Today: 30 April 2026
Browse Category

TSX:EDV 9 October 2025 - 28 January 2026

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 fell 0.3% to 10,177.85 as a stronger pound hit overseas earners. Gold reached a record above $5,300 an ounce, boosting miners, while Marston’s dropped up to 16% on flat 17-week sales. Traders awaited the U.S. Fed’s policy decision later Wednesday. Oil prices eased but held near four-month highs after U.S. supply disruptions.
28 January 2026
········
FTSE 100 slips as Barclays takes a hit from Trump’s credit-card cap push; gold miners climb

FTSE 100 slips as Barclays takes a hit from Trump’s credit-card cap push; gold miners climb

Barclays dropped 4% after U.S. President Trump called for a 10% cap on credit-card interest rates, weighing on UK stocks. The FTSE 100 slipped 0.1% by 0823 GMT, while sterling rose 0.3% to about $1.34. Miners gained as gold hit a record $4,563.61 an ounce. HSBC and other European banks also fell on concerns over U.S. policy risks.
12 January 2026
······
FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

The FTSE 100 closed at a record high near 9,548 in early October, up 15–17% year-to-date, led by surges in banks, miners, and healthcare stocks. Gains followed strong earnings, regulatory relief, and gold topping $4,000/oz. A weak pound boosted international firms’ profits. Political shifts and a new UK-India trade deal also moved markets, while Middle East tensions kept oil and gold prices elevated.
9 October 2025
······

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Go toTop